期刊
CURRENT ONCOLOGY
卷 28, 期 5, 页码 4093-4108出版社
MDPI
DOI: 10.3390/curroncol28050347
关键词
immunotherapy; small cell lung cancer; checkpoint inhibitors; PD-1; PD-L1; CTLA-4
类别
资金
- Amgen Canada
- AstraZeneca Canada Inc.
- Eisai Canada Limited
- Hoffman La Roche Canada
- Jazz Pharmaceuticals Canada Inc.
- Novartis Canada
- Sanofi Canada
- Pfizer Canada Inc.
Small cell lung cancer is a disease with aggressive features and limited treatment options. Immunotherapy has changed the treatment landscape for many cancers, including SCLC, but questions remain on how to best implement and enhance responses to this treatment.
Small cell lung cancer (SCLC) remains a poorly understood disease with aggressive features, high relapse rates, and significant morbidity as well as mortality, yet persistently limited treatment options. For three decades, the treatment algorithm of SCLC has been stagnant despite multiple attempts to find alternative therapeutic options that could improve responses and increase survival rates. On the other hand, immunotherapy has been a thriving concept that revolutionized treatment options in multiple malignancies, rendering previously untreatable diseases potentially curable. In extensive stage SCLC, immunotherapy significantly altered the course of disease and is now part of the treatment algorithm in the first-line setting. Nevertheless, the important questions that arise are how best to implement immunotherapy, who would benefit the most, and finally, how to enhance responses.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据